The role of TRPV1 in chronic prostatitis: a review
- PMID: 39364048
- PMCID: PMC11446813
- DOI: 10.3389/fphar.2024.1459683
The role of TRPV1 in chronic prostatitis: a review
Abstract
Chronic prostatitis is a prevalent male urinary system disorder characterized by pelvic discomfort or pain, bladder dysfunction, sexual dysfunction, and infertility. Pain and lower urinary tract symptoms (LUTS) are the most common symptoms, significantly impacting patients' quality of life and driving them to seek medical attention. Transient receptor potential vanilloid subtype 1 (TRPV1) is a non-selective calcium ion-dependent cation channel in the TRPV channel family that is widely distributed in neural tissue and plays a role in signal transmission. In this review, we provide a comprehensive overview of the current understanding of the role of TRPV1 in chronic prostatitis. The discussion focuses on the connection between TRPV1 and prostatitis pain and LUTS, and highlights the potential for targeting this channel in the development of novel treatment strategies.
Keywords: TRPV1 channel; lower urinary tract symptoms; pain; prostatitis; therapeutic target.
Copyright © 2024 Jiang, Luo, Long and Chen.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Targeting TRPV1 channels in desensitized neural afferent pathways may help mitigate pain and lower urinary tract symptoms caused by prostatitis.Front Pharmacol. 2025 Feb 25;16:1541684. doi: 10.3389/fphar.2025.1541684. eCollection 2025. Front Pharmacol. 2025. PMID: 40070569 Free PMC article.
-
TRPV1 in experimental autoimmune prostatitis.Prostate. 2020 Jan;80(1):28-37. doi: 10.1002/pros.23913. Epub 2019 Oct 1. Prostate. 2020. PMID: 31573117 Free PMC article.
-
Enhancement sensitivity of TRPV1 in dorsal root ganglia via the SP-NK-1 pathway contributes to increased bladder organ sensitivity caused by prostatitis.Front Neurosci. 2024 Oct 31;18:1484980. doi: 10.3389/fnins.2024.1484980. eCollection 2024. Front Neurosci. 2024. PMID: 39544909 Free PMC article.
-
Transient receptor potential vanilloid subtype 1: A potential therapeutic target for fibrotic diseases.Front Physiol. 2022 Aug 15;13:951980. doi: 10.3389/fphys.2022.951980. eCollection 2022. Front Physiol. 2022. PMID: 36045746 Free PMC article. Review.
-
Chronic prostatitis: management strategies.Drugs. 2009;69(1):71-84. doi: 10.2165/00003495-200969010-00005. Drugs. 2009. PMID: 19192937 Review.
Cited by
-
Targeting the brain-gut-prostate axis in chronic prostatitis: mechanisms and therapeutics.Front Endocrinol (Lausanne). 2025 Jul 4;16:1628094. doi: 10.3389/fendo.2025.1628094. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40687578 Free PMC article.
-
Targeting TRPV1 channels in desensitized neural afferent pathways may help mitigate pain and lower urinary tract symptoms caused by prostatitis.Front Pharmacol. 2025 Feb 25;16:1541684. doi: 10.3389/fphar.2025.1541684. eCollection 2025. Front Pharmacol. 2025. PMID: 40070569 Free PMC article.
-
Efficacy of Different Acupuncture Therapies for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Network Meta-Analysis.J Pain Res. 2025 Jul 17;18:3653-3673. doi: 10.2147/JPR.S530646. eCollection 2025. J Pain Res. 2025. PMID: 40693196 Free PMC article. Review.
References
-
- Apostolidis A., Gonzales G. E., Fowler C. J. (2006). Effect of intravesical resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur. Urol. 50 (6), 1299–1305. 10.1016/j.eururo.2006.04.006 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources